Evolent Health, Inc.
EVH · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,554,741 | $1,963,896 | $1,352,013 | $907,957 |
| % Growth | 30.1% | 45.3% | 48.9% | – |
| Cost of Goods Sold | $2,187,388 | $1,503,426 | $1,035,429 | $657,551 |
| Gross Profit | $367,353 | $460,470 | $316,584 | $250,406 |
| % Margin | 14.4% | 23.4% | 23.4% | 27.6% |
| R&D Expenses | $0 | $0 | $27,000 | $0 |
| G&A Expenses | $0 | $0 | $0 | $219,499 |
| SG&A Expenses | $263,050 | $358,110 | $269,269 | $219,499 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $144,788 | $173,571 | $16,673 | $73,318 |
| Operating Expenses | $407,838 | $531,681 | $312,942 | $292,817 |
| Operating Income | -$40,485 | -$71,211 | $3,642 | -$42,411 |
| % Margin | -1.6% | -3.6% | 0.3% | -4.7% |
| Other Income/Exp. Net | -$22,551 | -$131,194 | -$65,719 | $12,610 |
| Pre-Tax Income | -$63,036 | -$202,405 | -$62,077 | -$29,801 |
| Tax Expense | -$1,413 | -$89,365 | -$43,376 | $483 |
| Net Income | -$61,623 | -$113,040 | -$19,164 | -$37,601 |
| % Margin | -2.4% | -5.8% | -1.4% | -4.1% |
| EPS | -0.81 | -1.28 | -0.2 | -0.36 |
| % Growth | 36.7% | -540% | 44.4% | – |
| EPS Diluted | -0.81 | -1.28 | -0.2 | -0.36 |
| Weighted Avg Shares Out | 114,682 | 111,251 | 93,699 | 86,067 |
| Weighted Avg Shares Out Dil | 114,682 | 111,251 | 93,699 | 86,067 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,544 | $5,256 | $1,369 | $407 |
| Interest Expense | $24,722 | $54,205 | $15,572 | $25,425 |
| Depreciation & Amortization | $123,168 | $123,415 | $90,251 | $60,037 |
| EBITDA | $84,854 | -$24,785 | $43,746 | $55,661 |
| % Margin | 3.3% | -1.3% | 3.2% | 6.1% |